Table 1.
Clinicopathologic Characteristics of Patients with Different Molecular Subtypes of Breast Carcinoma
| Parameter | Total | Molecular subtype | |||
|---|---|---|---|---|---|
| Luminal | HER2 | Basal like | Unclassified | ||
| Sample size (%) | 226 | 65 (29%) | 65 (29%) | 86 (38%) | 10 (4%) |
| Mean age (y) ± SD | 61 ± 15 | 64 ± 16 | 61 ± 15 | 59 ± 15 | 65 ± 12 |
| Race | |||||
| White | 202 (90%) | 62 (95%) | 59 (92%) | 73 (85%) | 9 (90%) |
| African American | 24 (10%) | 3 (5%) | 5 (8%) | 13 (15%) | 1 (10%) |
| AJCC stage | |||||
| Stage 1 | 91 (41%) | 20 (31%) | 30 (46%) | 35 (41%) | 6 (60%) |
| Stage 2 | 95 (42%) | 31 (470%) | 24 (37%) | 37 (43%) | 3 (30%) |
| Stage 3 | 19 (9%) | 7 (11%) | 4 (6%) | 7 (8%) | 1 (10%) |
| Stage 4 | 7 (3%) | 3 (5%) | 1 (2%) | 3 (3%) | 0 |
| Tumor status | |||||
| T1 | 120 (53%) | 26 (40%) | 38 (58%) | 48 (56%) | 8 (80%) |
| T2 | 84 (37%) | 29 (45%) | 21 (32%) | 33 (38%) | 1 (10%) |
| T3 | 9 (4%) | 3 (5%) | 2 (3%) | 3 (4%) | 1 (10%) |
| T4 | 9 (4%) | 6 (8%) | 1 (2%) | 2 (2%) | 0 |
| Node status | |||||
| N0 | 117 (52%) | 28 (44%) | 36 (58%) | 46 (53%) | 7 (70%) |
| N1 | 55 (24%) | 15 (23%) | 18 (27%) | 20 (23%) | 2 (20%) |
| N2 | 11 (5%) | 4 (6%) | 1 (2%) | 5 (6%) | 1 (10%) |
| N3 | 5 (2%) | 2 (3%) | 2 (3%) | 1 (1%) | 0 |
| Nx | 38 (17%) | 16 (25%) | 8 (12%) | 14 (16%) | 0 |
| Metastasis status | |||||
| M0 | 215 (95%) | 62 (95%) | 63 (96%) | 80 (93%) | 8 (80%) |
| M1 | 6 (3%) | 3 (5%) | 1 (2%) | 2 (2%) | 0 |
| Mx | 5 (2%) | 0 | 1 (2%) | 4 (5%) | 2 (20%) |